Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $45
Enovis Corporation
Enovis Corporation ENOV | 0.00 |
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:
ENOV) with a Buy and lowers the price target from $50 to $45.
